Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose more than 13% in the second quarter, product revenue increased 11% month-on-month, and the second half of the year will welcome multi-pipeline catalysts

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 13%. As of press release, it had risen 12.11% to HK$16.29, with a turnover of HK$69.7039 million.

According to the news, on the evening of August 6, Zaiding Pharmaceutical announced financial results for the second quarter of 2026, as well as recent product highlights and company progress. According to financial reports, the company's total revenue for the second quarter of 2026 was US$106.3 million, and net product revenue was US$105.8 million, up 11% month-on-month, thanks to Zelle's steady performance and the continued growth of Agamod's sales.

It is worth mentioning that the company has advanced several global oncology and immunization pipeline projects to key clinical and registration milestones, and the second half of 2026 is expected to usher in a number of important pipeline catalysts. Among them, global phase 1 data on Zoci combined with PD-L1 inhibitors for first-line small cell lung cancer (SCLC) will be announced at the 2026 ESMO conference; it is planned to launch a registered phase 3 study later this year. The ZL-1503 global phase 1/1b study continues to advance, and it is expected that the first preliminary human data will be obtained in the second half of 2026.